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Functionally impaired plasmacytoid dendritic cells
and non-haematopoietic sources of type I
interferon characterize human autoimmunity
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Miriam Wittmann 1,2, Paul Emery 1,2, George C. Tsokos 3 & Edward M. Vital 1,2✉
Autoimmune connective tissue diseases arise in a stepwise fashion from asymptomatic
preclinical autoimmunity. Type I interferons have a crucial role in the progression to estab-
lished autoimmune diseases. The cellular source and regulation in disease initiation of these
cytokines is not clear, but plasmacytoid dendritic cells have been thought to contribute to
excessive type I interferon production. Here, we show that in preclinical autoimmunity and
established systemic lupus erythematosus, plasmacytoid dendritic cells are not effector cells,
have lost capacity for Toll-like-receptor-mediated cytokine production and do not induce T
cell activation, independent of disease activity and the blood interferon signature. In addition,
plasmacytoid dendritic cells have a transcriptional signature indicative of cellular stress and
senescence accompanied by increased telomere erosion. In preclinical autoimmunity, we
show a marked enrichment of an interferon signature in the skin without infiltrating immune
cells, but with interferon-κ production by keratinocytes. In conclusion, non-hematopoietic
cellular sources, rather than plasmacytoid dendritic cells, are responsible for interferon
production prior to clinical autoimmunity.
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Systemic lupus erythematosus (SLE) and other autoimmuneconnective tissue diseases are a heterogeneous group ofconditions. The pathogenesis of these diseases is incom-
pletely understood. The most universal immune abnormality is
the presence of autoantibodies targeting nuclear antigens. The
dysregulation of the type I interferon (IFN) axis also has a fun-
damental role1,2. Many lupus susceptibility genes are related to
the IFN pathway3–7. However, IFN activity is more variable;
60–80% of SLE patients exhibit increased expression of
interferon-stimulated genes (ISGs) in peripheral blood8–11.
Autoimmune connective tissue diseases are now recognized to
arise in a stepwise fashion from asymptomatic preclinical auto-
immunity. Autoantibodies precede symptoms by years and are far
more common than clinical autoimmune disease12–16. Hence,
autoantibody-positive individuals constitute an At-Risk popula-
tion of whom a minority will develop clinical autoimmunity. A
key determinant of progression from At-Risk to established
clinical autoimmune disease is the level of IFN activity12. In
established SLE, IFN activity is particularly associated with
cutaneous involvement. It also predicts future flares and
severity8,17–19. In the present study, we, therefore, asked how IFN
production is controlled and regulated at both the preclinical and
established autoimmune disease stages.
Most hematopoietic and non-hematopoietic cells are capable of
producing type I IFNs (IFN-α, -β, -κ, -ω, -ε) as the first line of
defense against viral infections. Nevertheless, much previous
research on IFN production has focused on plasmacytoid den-
dritic cells (pDCs). pDCs from otherwise healthy individuals
produce particularly large amounts of type I IFNs upon recog-
nition of viral antigens via endosomal toll-like receptor 7 (TLR7)
and TLR920,21. Engagement of TLRs within endosomal com-
partments with these ligands leads to activation of IRF7 and NF-
κB pathways and eventually production of IFN-α and other pro-
inflammatory cytokines (TNF, IL-6)22. Apart from this secretory
function, pDCs exhibit antigen-presentation properties inducing
both immunogenic and tolerogenic T-cell responses23–28. Con-
versely, the IFN-α-producing capacity of pDCs has been shown to
be impaired in melanoma and ovarian cancer; tumor-infiltrating
pDCs do not produce IFN-α but their presence actually promotes
tumor growth29–31. Additionally, the hepatitis B virus can inter-
fere with the TLR9 pathway by blocking MyD88-IRAK4 signaling
and Sendai virus by targeting IRF7, while lymphocytic chor-
iomeningitis virus (LCMV) compromises the capacity of pDCs to
secrete type I IFNs32–34.
In the context of autoimmunity, endogenous nucleic acids
forming immune complexes with autoantibodies have been pro-
posed as a stimulus for pDC activation35–38. While it is therefore
natural to assume that pDCs are dominant producers of IFN-α in
SLE, in fact, the existing literature is complex and contradictory.
Previous studies have reported both higher and lower numbers of
pDCs in blood39,40. Unsorted PBMCs from SLE patients have
been shown to produce lower levels of IFN-α in response to
TLR9 stimulation, while other studies reported enhanced TLR7-
mediated IFN-α production by pDCs of SLE patients41,42. It is not
clear whether any alteration in the pDC phenotype is the result of
chronic inflammation or therapy, nor what underlying mechan-
ism determines their function in the early stages of human
autoimmunity.
In order to resolve these contradictions, here we assess pDC
phenotype, function, and transcriptomic profile in At-Risk indi-
viduals who are therapy-naive and do not have tissue inflam-
mation as well as in established SLE and primary Sjögren’s
Syndrome (pSS). We show that pDC numbers, TLR-mediated
cytokine production, and T-cell-activating capacity are decreased
prior to the onset of SLE. This impairment is unrelated to the type
I IFN signature in the blood. Instead, pDCs have a transcriptomic
profile indicative of cellular stress and senescence. By contrast, we
show that non-hematopoietic tissue-resident cells in the skin are
not passive targets. Rather, these cells actively contribute to
aberrant type I IFN production in both preclinical and established
autoimmunity. These findings provide unique insights into the
source and regulation of type I IFNs in human autoimmune
disease.
Results
pDC numbers are reduced in preclinical autoimmunity and
SLE. Peripheral blood pDCs were enumerated and immuno-
phenotyped from freshly isolated peripheral blood mononuclear
cells (PBMCs) using flow cytometry. We analyzed samples from
At-Risk individuals (defined by ANA+, ≤1 clinical criterion for
SLE, symptom duration <12 months and treatment-naive; n=
64), patients with SLE (n= 81) and pSS (n= 21) as well as age-
and sex-matched healthy controls (n= 37). Clinical character-
istics and treatment of SLE patients can be seen in Supplementary
Table 1. pDCs were gated as CD3−CD19−CD14−CD56−CD11c−
HLA-DR+CD123+CD303+ cells (Fig. 1a). The average percen-
tage of pDCs in PBMCs was significantly decreased in patients
with SLE and pSS in comparison with healthy controls, a finding
which was also observed in treatment-naive At-Risk individuals
(Fig. 1b). The percentage and absolute numbers of pDCs in the
peripheral blood of all samples analyzed were closely correlated
(Supplementary Fig. 1a).
To determine whether the reduction of circulating pDCs was
associated with blood ISG expression and other clinical features,
we evaluated the expression of a previously validated IFN score
(IFN score A) in PBMCs using TaqMan in all sample groups
described above8. Increased type I IFN activity, as assessed by IFN
score A, was observed in patients with SLE and pSS as well as At-
Risk individuals compared to healthy controls, but the reduction
of peripheral blood pDCs described above was not associated
with the higher expression of IFN score A (Fig. 1c–f). Although
IFN score A was associated with an increased number of
extractable nuclear antigen (ENA) antibodies, no association was
found between the percentage of pDCs and either IFN score A or
ENA antibodies in any of the sample groups (Supplementary
Fig. 1b, c). Additionally, in SLE patients the reduction of
circulating pDCs was independent of disease activity (Fig. 1g),
treatment with hydroxychloroquine (Fig. 1h), other immunosup-
pressants (Fig. 1i), or prednisolone (Fig. 1j). Apart from that, the
reduction of circulating pDCs in At-Risk individuals, patients
with SLE and pSS was not associated with the total lymphocyte
count, which is commonly low in SLE patients (Supplementary
Fig. 1d–f).
pDCs from healthy controls, At-Risk individuals, and SLE
patients were analyzed for the surface expression of multiple
molecules known to be important in regulating their immune
functions (Supplementary Fig. 2a–f). pDCs in SLE patients
showed no statistically significant difference in the expression of
HLA-DR or BDCA-2 (CD303). On the other hand, CD123 (IL-
3R) and ILT2 (CD85j) were found to be upregulated on pDCs of
SLE patients compared to healthy controls (P < 0.001). Interest-
ingly, CD317 (BST2; tetherin), a molecule is known to be induced
by type I IFNs also presented higher expression on pDCs of SLE
patients (P < 0.05); however, its ligand ILT7 (CD85g) appeared to
be downregulated on pDCs of SLE patients (P < 0.05).
TLR-stimulated pDCs produce less cytokines in autoimmunity.
The production of IFN-α and other pro-inflammatory cytokines
(e.g. TNF) in response to TLR-mediated stimulation is the hall-
mark of normal pDC function. To evaluate the capacity of
cytokine production by pDCs, we stimulated freshly isolated
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PBMCs from At-Risk individuals (n= 26), patients with estab-
lished SLE (n= 40) and pSS (n= 7) alongside healthy controls
(n= 14) for 6 h with TLR9 (ODN 2216) or TLR7 (ORN R-2336)
agonists. We measured both IFN-α and TNF produced by CD3−
CD19−CD14−CD56−CD11c−HLA-DR+CD123+CD303+ pDCs
using intracellular staining. No IFN-α and/or TNF production by
pDCs was detected in any of the samples without external sti-
mulation. While pDCs from healthy controls produced large
amounts of IFN-α in response to TLR9 or TLR7 agonists, pDCs
from SLE patients showed little or no cytokine production
(Fig. 2a). Furthermore, TLR9- and TLR7-mediated IFN-α pro-
duction was diminished in pDCs from patients with pSS similarly
to SLE (Fig. 2c, d). Although TLR9-mediated IFN-α production
was similarly reduced in At-Risk individuals, their pDCs seemed
to partially maintain some TLR7-mediated IFN-α production
(Fig. 2d). TLR9- and TLR7-mediated TNF production was also
significantly decreased in pDCs from patients with SLE and pSS
compared to healthy controls (Fig. 2b), whilst pDCs from At-Risk
individuals showed the same trend as for IFN-α production,
partially maintaining some TLR7-mediated TNF production
(Fig. 2e, f).
We next evaluated whether there was any association between
IFN-α production by pDCs and overall blood type I IFN activity
as measured by IFN score A. We found no association between
the levels of TLR-mediated IFN-α production and the level of IFN
score A in patients with SLE and pSS as well as At-Risk
individuals (Supplementary Fig. 3a–d). To confirm that these
findings were not due to differences in TLR expression, we
measured the expression levels of both TLR9 and TLR7 using
flow cytometry. pDCs from At-Risk individuals and SLE patients
showed similar expression levels of both receptors compared to
those of healthy controls (Fig. 2g, h). There was no correlation
a
c
g h ji
d e f
b
S
S
C
H
LA
-D
R
C
D
12
3
FSC
CD303
Lineage
1.5
1.0
1.0
0.5
0.5
%
 p
D
C
s 
in
 P
B
M
C
s
%
 p
D
C
s 
in
 P
B
M
C
s
%
 p
D
C
s 
in
 P
B
M
C
s
0.0
0.0
1.0
0.8
0.6
0.4
0.2
0.0
%
 p
D
C
s 
in
 P
B
M
C
s
1.0
0.8
0.6
0.4
0.2
0.0
%
 p
D
C
s 
in
 P
B
M
C
s
1.0
nsns
0.8
0.6
0.4
0.2
0.0
%
 p
D
C
s 
in
 P
B
M
C
s
1.0
0.8
0.6
0.4
0.2
0.0
–10
lnactive SLE None HCQ None MTX AZA MMF
Prednisolone dose (mg)
0 20 40Active SLE
–8 –6
Healthy Controls At-Risk SLE pSS
lFN Score A (–dCT)
–4
R2 = 0.017
R2 = 0.03
R2 = 0.004
R2 = 0.04
R2 = 0.03
–2 –10 –8 –6
lFN Score A (–dCT)
–4 –2 –10 –8 –6
lFN Score A (–dCT)
–4 –20 –10 –8 –6
lFN Score A (–dCT)
–4 –2 0
1.0
0.5
%
 p
D
C
s 
in
 P
B
M
C
s
0.0
1.0
0.5
%
 p
D
C
s 
in
 P
B
M
C
s
0.0
1.0
0.5
%
 p
D
C
s 
in
 P
B
M
C
s
0.0
HC At-Risk SLE pSS
PBMCs
pDCs
Lin– HLA-DR+
Fig. 1 Decrease in circulating pDCs in autoimmunity is independent of disease activity and therapy. a Gating strategy to identify the pDC population
within PBMCs: pDCs are characterized by the lack of expression of lineage markers (CD3, CD19, CD56, CD14, CD11c), intermediate to high expression of
HLA-DR, high expression of CD123 (IL-3R) and CD303 (BDCA-2). b Average percentage of pDCs in PBMCs of age- and sex-matched healthy
controls (HC; n= 37), At-Risk individuals (At-Risk; n= 64), patients with systemic lupus erythematosus (SLE; n= 81) and primary Sjögren’s Syndrome
(pSS; n= 21). c–f Association between the percentage of pDCs in PBMCs and type I IFN activity in the blood (IFN score A) in HC, At-Risk, SLE, and pSS.
g Percentage of pDCs in PBMCs in SLE patients with inactive and active disease. h Percentage of pDCs in PBMCs in SLE patients treated with or without
hydroxychloroquine (HCQ). i Percentage of pDCs in PBMCs in SLE patients treated with other immunosuppressants (MTX = methotrexate, AZA =
azathioprine, MMF = mycophenolate mofetil). j Association between the percentage of pDCs in PBMCs and the dose of prednisolone in patients with
SLE. Data are represented as mean ± SEM. ns = not significant; ****P < 0.0001. Two-way ANOVA (b), nonlinear regression (c–f and j), unpaired two-tailed
t-test (g–i).
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between IFN-α production and the intracellular expression of
either TLR9 or TLR7 (Supplementary Fig. 3e, f).
Interestingly, while culturing PBMCs, we observed that a
population within monocytes was characterized by no expression
of HLA-DR, which is expressed by all pDCs, but a positive
expression of CD303 (BDCA-2), which was previously thought to
be a pDC-specific marker and used in immunohistochemistry.
These cells showed no response to TLR stimulation, as neither IFN-
α nor TNF production was detected (Supplementary Fig. 3g, h).
IL-3 triggers TLR-independent production of IL-6 by pDCs.
IL-3 is known to maintain pDC survival in vitro and to enhance
IFN-α production upon TLR-mediated stimulation43,44. We
confirmed that pre-treatment for 24 h with IL-3 amplified IFN-α
production by both TLR9- and TLR7-stimulated pDCs from
healthy controls (n= 6). However, a statistically significant
enhancement in IFN-α production was not seen in pDCs of At-
Risk individuals (n= 4) and SLE patients (n= 7) (Fig. 3a, b).
Furthermore, we discovered an additional function of pDCs; IL-3
triggered the spontaneous production of IL-6 by pDCs without
any exogenous TLR-mediated stimulation. In contrast to the
defective TLR-mediated IFN-α and TNF production in pDCs
from SLE patients and At-Risk individuals we described above,
this TLR-independent IL-6 production upon IL-3 stimulation was
not impaired in pDCs of any of the groups tested (Fig. 3c, d).
T-cell activation by pDCs is impaired in autoimmunity.
Although pDCs possess antigen-presentation properties and can
trigger T-cell responses, little is known about the capacity of
pDCs in SLE to induce T-cell proliferation and activation. We co-
cultured freshly isolated pDCs from patients with active SLE, At-
Risk individuals, and healthy controls with CellTrace Violet-
labeled allogeneic naive CD4+ T cells in the presence of low ratio
anti-CD3/CD28 beads for 5 days (Fig. 4a). Although pDCs from
all groups induced T-cell proliferation, pDCs from SLE patients
and At-Risk individuals were substantially less efficient in indu-
cing T-cell proliferation (Fig. 4b). pDCs are also known to trigger
the induction of FoxP3+ T cells (a marker of T-cell activation).
Following the same protocol as above, we found that fewer
CD25highFoxP3+ cells were generated from naive CD4+ T cells
after 5 days of co-culturing with pDCs from SLE patients and At-
Risk individuals in comparison with pDCs from healthy controls
(Fig. 4c, d).
For additional confirmation that pDCs from At-Risk indivi-
duals and SLE patients were not switching to an antigen-
presenting phenotype, we tested antigen uptake from the cells
using DQ Ovalbumin. First, pDCs were purified from freshly
isolated PBMCs as described above and were then cultured alone
or with 10 μg/mL DQ Ovalbumin. After 18 h, pDCs were
harvested and DQ Ovalbumin processing was analyzed by flow
cytometry based on the level of mean fluorescence intensity.
Almost all pDCs from healthy controls were able to internalize
and process DQ Ovalbumin as compared to the negative control.
However, pDCs from both At-Risk individuals and SLE patients
had significantly reduced antigen uptake, indicating impaired
antigen processing and presenting properties (Fig. 4e).
To investigate the ability of pDCs to trigger cytokine
production by T cells, we first co-cultured pDCs from patients
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Fig. 2 TLR-stimulated pDCs produce less IFN-α and TNF in autoimmunity. a, b Freshly isolated PBMCs were cultured in the absence or presence of TLR9
(ODN 2216) or TLR7 (ORN R-2336) agonists for 6 h, then IFN-α and TNF production by pDCs was measured using intracellular staining. Results shown are
representative of healthy control (HC) and a patient with SLE. The average percentage of IFN-α produced by TLR9-stimulated (c) and TLR7-stimulated (d)
pDCs in HC (n= 14), At-Risk (n= 26), SLE (n= 40), and pSS (n= 7) patients. The average percentage of TNF produced by TLR9-stimulated (e) and TLR7-
stimulated (f) pDCs in HC (n= 14), At-Risk (n= 26), SLE (n= 40), and pSS (n= 7) patients. g, h Intracellular expression of TLR9 and TLR7 was measured
using flow cytometry in HC (n= 7), At-Risk (n= 8), and SLE (n= 19) patients. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001. Two-way ANOVA (c–h).
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with active SLE, At-Risk individuals, and healthy controls with
allogeneic naive CD4+ T cells in the presence of low ratio anti-
CD3/CD28 beads for 5 days before adding PMA/Ionomycin in
the last 5 h of the culture. In comparison with T cells alone, pDCs
from healthy controls enhanced the production of TNF (34.07%
vs. 48.18%), IFN-γ (5.05% vs. 6.01%), and IL-10 (1.75% vs.
3.42%) from the co-cultured T cells (Fig. 4f–k). However, pDCs
from SLE patients suppressed the production of all cytokines
measured; TNF (34.07% vs. 27.95%), IFN-γ (5.05% vs. 3.65%),
and IL-10 (1.75% vs. 0.83%). Similar results were observed for
pDCs from At-Risk Individuals. In summary, pDCs from SLE
patients and At-Risk individuals exhibit a decreased capacity for
triggering T-cell proliferation and activation, whilst they actively
inhibited cytokine production by T cells.
pDCs cluster according to ISG expression in RNA-sequencing.
To investigate disease-associated transcriptional changes in pDCs,
we purified pDCs from healthy controls (n= 8), At-Risk indivi-
duals (n= 4) and SLE patients (n= 13) by negative selection
then sorted the cells to achieve purity >99% based on CD304
(BDCA-4) expression. We sequenced the RNA extracted from
sorted pDCs using Smart-seq2 for sensitive full-length tran-
scriptomic profiling.
A major source of variability amongst the samples was due to
the expression of ISGs. In the RNA-sequencing analysis, pDCs
clustered according to ISG expression rather than according to
the clinical diagnosis. In order to control for this variability, we
therefore first scored each sample based on the expression profile
of a core set of ISGs (IFN score). The expression level of IFN
score in pDCs from healthy controls (95% CI) was used to assign
each sample to IFNlow or IFNhigh subgroups (Fig. 5a). As
expected, pDCs from SLE patients were characterized by a range
of IFN scores, but overall exhibited a higher IFN score than pDCs
from healthy controls and At-Risk individuals (Fig. 5b). pDCs
from most At-Risk individuals presented a higher IFN score
compared to pDCs from healthy controls and three of the four
were assigned to the IFNhigh subgroup. pDC RNA-sequencing
data was consistent with the blood IFN score used for
categorization. Common ISGs (MX1, XAF1, IFI44, RSAD2) were
found to be upregulated in the majority of pDCs in IFNhigh SLE
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patients and At-Risk individuals, whilst pDCs of IFNlow SLE
patients showed similar expression levels to those of healthy
controls (Fig. 5c).
pDCs of IFN subgroups have distinct transcriptional profiles.
The analysis of IFNlow SLE patients revealed 543 transcripts that
were significantly (FDR < 5%) differentially expressed (Fig. 5d).
These were particularly enriched for IL-4 and IL-13 signaling, IL-
10 signaling, cell migration, and pathogen interaction pathways,
among others (Supplementary Fig. 4a). Amongst the upregulated
genes were those corresponding to chemokines, for instance,
CXCL3, CXCL2, and CXCL16 (Supplementary Fig. 5a). A detailed
a
c
f
h
j
i
k
g
d e
bT cells alone
No stimulation
T cells + HC pDCs
anti-CD3/CD28
T cells + SLE pDCs
anti-CD3/CD28
0.50%
9.90%
FoxP3
34.07%
5.05%
1.75% 3.42% 0.83%
6.01% 3.65%
C
D
4
C
D
4
C
D
4
48.18%
TNF
lL-10
lFN-γ
27.95%
T cells alone
T cells alone T cells + HC pDCs
T cells + HC pDCs T cells + SLE pDCs
T cells + SLE pDCs
T cells alone T cells + HC pDCs T cells + SLE pDCs
3.90%
C
ou
nt
C
D
25
%
 C
D
25
+
F
ox
P
3+
 T
 c
el
ls
D
Q
-o
va
lb
um
in
 u
pt
ak
e 
(M
F
l)
%
 C
el
lT
ra
ce
 V
io
le
t n
eg
 T
 c
el
ls
%
 T
N
F
-p
ro
du
ci
ng
 T
 c
el
ls
%
 lF
N
-γ
-p
ro
du
ci
ng
 T
 c
el
ls
%
 lL
-1
0-
pr
od
uc
in
g 
T
 c
el
ls
CellTrace Violet
8.65% 42.43% 26.08%
80
60
40
20
0
80
60
40
20
0
15
10
5
0
8
6
4
2
0
15 6000
4000
2000
0
10
5
0
HC At-RisK SLE
HC
HC At-Risk SLE
ns
ns
ns
ns
ns
ns
At-RisK Untreated DQ-ovalbuminSLE
HC At-RisK SLE
HC At-RisK SLE
HC At-RisK SLE
T cells alone
anti-CD3/CD28
T cells + HC pDCs
anti-CD3/CD28
T cells + SLE pDCs
anti-CD3/CD28
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19918-z
6 NATURE COMMUNICATIONS |         (2020) 11:6149 | https://doi.org/10.1038/s41467-020-19918-z | www.nature.com/naturecommunications
table of the top differentially expressed genes in pDCs of IFNlow
SLE patients can be found in Supplementary Table 2.
In IFNhigh SLE patients, we found 674 transcripts that were
significantly (FDR < 5%) differentially expressed (Fig. 5d). Unsur-
prisingly, these genes were found to be heavily enriched for IFN-
response pathways (Supplementary Fig. 4b), but also pathways
related to DNA repair and MAPK signaling. Several phosphatases
are known to dephosphorylate MAP kinases (DUSP1, DUSP2,
DUSP5, and DUSP8), transcriptional repressors associated with
cell differentiation (HESX1, ETV3), and NF-κB inhibitors
(NFKBIA, NFKBID) were found to be upregulated in IFNhigh
SLE patients (Supplementary Fig. 5b–d). A detailed table of the
top differentially expressed genes in pDCs of IFNhigh SLE patients
can be found in Supplementary Table 3.
In At-Risk individuals, we found 114 transcripts that were
significantly (FDR < 5%) differentially expressed compared to
healthy controls (Fig. 5d). The main pathways enriched were
associated with regulation of innate immune responses, response
to type I IFN and viruses as well as response to reactive oxygen
species and hydrogen peroxide (Supplementary Fig. 7a). A
detailed table of the top differentially expressed genes in pDCs
of At-Risk individuals can be found in Supplementary Table 5.
Between At-Risk and IFNlow SLE, there were 285 differentially
expressed transcripts (Supplementary Fig. 6a). A detailed table of
the top differentially expressed of these is shown in Supplemen-
tary Table 6. Comparing At-Risk and IFNhigh SLE, there were 356
differentially expressed transcripts (Supplementary Fig. 7b). Due
to the fact that At-Risk pDCs were clustered into the IFNhigh
subgroup, IFN-response pathways were similarly enriched. A
detailed table of the top differentially expressed genes in pDCs of
At-Risk individuals and IFNhigh SLE patients can be found in
Supplementary Table 7. Amongst the commonly enriched
pathways of At-Risk and SLE pDCs compared to healthy controls
were regulation of MAPK activity, neutrophil regulation, and
chemotaxis (Supplementary Fig. 7b).
Given that pDCs clustered according to IFN status rather than
clinical diagnosis, we analyzed the differentially expressed
transcripts in the IFNhigh and IFNlow subgroups (including both
At-Risk individuals and SLE patients) in comparison to the
healthy controls. We also analyzed those pathways that were
commonly involved in both subgroups (Fig. 5e). The pathways
are common to both subgroups related to IL-10 signaling, RAF-
independent MAPK 1/3 activation, negative regulation of MAPK
pathways, and chemokine receptor binding (Supplementary
Fig. 4c).
We also evaluated the expression levels of multiple TLRs in the
pDCs of all samples (Supplementary Fig. 9). As expected, pDCs
from healthy controls, At-Risk individuals, and SLE patients
strongly expressed TLR9 and TLR7; however, no differences were
found among the different groups regardless of IFN activity, in
line with the intracellular expression of TLR9 and TLR7 at
protein level (Fig. 2g, h). Low expression of TLR1, TLR6, and
TLR10 was observed in pDCs with no difference among the
groups. No expression of TLR2, TLR3, TLR4, TLR5, and TLR8
was found in any of the samples. Additionally, no transcripts for
the 14 distinct subtypes of IFN-alpha were detected in the pDCs
of any sample. Neither other type I IFN transcripts (IFN-beta,
IFN-kappa, IFN-omega) nor transcripts for type III IFNs (IFN-
lambda) were found to be expressed in any of the samples
(Supplementary Fig. 10). Because it has been suggested that pDCs
migrate into inflamed tissues, we checked their expression of
chemokine receptors. No significant differences were detected in
the expression of chemokines and their receptors apart from the
ones described in pDCs of At-Risk individuals, IFNlow and
IFNhigh SLE patients (Supplementary Figs. 11 and 12).
pDCs exhibit immune senescence and stress in autoimmunity.
In vitro functional assays demonstrated that the decreased
secretory and antigen-presenting function was universally
observed in pDCs of SLE patients and At-Risk individuals,
independently of the IFN activity in their PBMCs. To investigate
which biological pathways contribute to this defective phenotype,
we, therefore, studied the transcripts differentially expressed in
pDCs of both IFNlow and IFNhigh SLE patients compared to those
of healthy controls. The little overlap between differentially
expressed genes in pDCs of IFNlow and IFNhigh SLE patients was
detected—there were 80 shared transcripts (Fig. 6a). Reactome
Pathway Enrichment of these transcripts showed that biological
processes related to MAPK family signaling, TLR signaling, IL-10
signaling, and chemotaxis were significantly enriched (Fig. 6b).
Amongst the 80 shared transcripts, there were upregulated genes
involved in cellular senescence and stress (ATG14, ATP7A,
DNAJB1), protein degradation in lysosomes (CTSL), negative
regulation of TLR signaling (IRAK3), negative regulation of
MAPK signaling (DUSP1, DUSP8) and negative regulation of
non-canonical NF-κB pathway (ZFP91), which are all known to
inhibit the production of type I IFNs and other pro-inflammatory
cytokines (Fig. 6c). Moreover, the shared transcripts included
upregulated genes for CXCL2 and CCL19 (Supplementary
Fig. 5a). For At-Risk individuals, the expression of most of the
shared transcripts showed the same trend as in SLE pDCs. In
keeping with the functional experiments, we did not see sub-
stantial differences in the transcriptomic profile of the 80 shared
transcripts when we compared At-Risk pDCs with those of
IFNlow and IFNhigh SLE patients (Supplementary Fig. 8). A
detailed table of the genes commonly differentially expressed in
pDCs of both IFNlow and IFNhigh SLE patients can be found in
Supplementary Table 4.
Since the transcriptomic data suggested pathways associated
with cellular senescence, we further investigated whether this
applied to the pDCs of SLE patients. Increased telomere erosion is
known to be related to cellular senescence, a feature that has been
found in other immune cells of patients with SLE but has not
Fig. 4 pDCs display impaired T-cell activation in autoimmunity. a Allogeneic naive CD4+ T cells were labeled with CellTrace Violet and cultured alone or
with pDCs purified from healthy controls (HC) or patients with active SLE for 5 days in the presence of anti-CD3/CD38 beads at ratio 2:1 to avoid excessive
T-cell activation and expansion. T-cell proliferation was analyzed by flow cytometry based on CellTrace Violet dilution. One representative experiment is
shown out of four independent experiments. b Average percentage of proliferated CD4+ T cells co-cultured with pDCs from healthy controls (n= 8), At-
Risk individuals (n= 7), and SLE patients (n= 7). c Induction of CD4+CD25highFoxP3+ T cells from naive CD4+ T cells co-cultured for 5 days with pDCs
from healthy controls or SLE patients in the presence of anti-CD3/CD28 beads at ratio 2:1. One representative experiment is shown out of three independent
experiments. d Percentage of CD4+CD25highFoxP3+ T cells derived from the co-culture with pDCs from healthy controls (n= 5), At-Risk individuals (n= 5),
and SLE patients (n= 5). f–k Allogeneic naive CD4+ T cells were cultured alone or with pDCs from healthy controls or SLE patients for 5 days in the
presence of anti-CD3/CD38 beads at ratio 2:1. On the fifth day, the cells were stimulated with PMA/Ionomycin, and the production of TNF (f), IFN-γ (h),
and IL-10 (j) by CD4+ T cells was measured by intracellular staining. One representative experiment is shown out of three independent experiments. The
average percentage of TNF (g), IFN-γ (i), and IL-10 (k) produced CD4+ T cells co-cultured with pDCs from healthy controls, At-Risk individuals, and SLE
patients. Data are represented as mean ± SEM. *P < 0.05; **P < 0.001; ***P < 0.0001; ns = not significant. Two-way ANOVA (b, d, e, g, i, k).
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previously been described in pDCs45. We purified pDCs from
healthy controls alongside SLE patients, which were then
hybridized with telomere PNA probe before analysis by flow
cytometry. The relative telomere length was calculated as the ratio
between the telomere signal of pDCs and the tetraploid control
cells (1301 cell line) with correction for the DNA index of G0/1
cells (Fig. 6d). The analysis confirmed that pDCs from SLE
patients had shorter telomere length compared to pDCs from
age- and sex-matched healthy controls (Fig. 6e).
RNA-sequencing data also suggested that genes related to
cellular stress are amongst the 80 shared transcripts. Thus, we
next sought to investigate the effect of oxidative stress on type I
IFN production in TLR-stimulated pDCs. Freshly isolated
PBMCs from healthy donors were exposed to increasing
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concentrations of H2O2 (0–500 μM) for 15 min before they were
stimulated with ODN 2216. IFN-α production was measured in
viable cells using flow cytometry. Cells showed high viability
(>90%) indicated by double negativity for Annexin V and 7-AAD
even at 6 h after exposure to high concentrations of H2O2
(Fig. 6f). We observed that oxidative stress—even at low
concentrations of H2O2—negatively regulated TLR-mediated
responses in pDCs leading to a gradual loss of their ability to
produce IFN-α (Fig. 6g).
IFN activity is enriched in the skin in preclinical auto-
immunity. Since professional IFN-α-producing cells such as
pDCs were functionally impaired in SLE, the source of the
aberrant type I IFN production seen in patients had yet to be
identified. We compared the level of expression of IFN score A in
blood with clinical disease activity in the two most common
organ manifestations, defining active disease as BILAG-2004 A or
B and inactive disease as BILAG-2004 C-E. We found that IFN
score A was associated with mucocutaneous disease activity (fold
difference 2.24 (95% CI 1.16–4.34); P= 0.017), but not with the
musculoskeletal disease (fold difference 0.97 (95% CI 0.44–2.09);
P= 0.927). For graphical representation, mean and SEM were
transformed using 2−dCt so that higher expression was shown as
a taller bar (Fig. 7a, b).
Next, we compared the fold increase in IFN score A in paired
blood and skin biopsies from At-Risk individuals and SLE
patients compared to healthy controls (Fig. 7c, d). We analyzed
blood samples from 114 SLE patients, 105 At-Risk individuals,
and 49 healthy controls. We also analyzed lesional skin biopsies
from 10 SLE patients and non-lesional skin biopsies from 10 At-
Risk individuals as well as skin biopsies from 6 healthy controls.
In At-Risk individuals compared to healthy controls, the mean
fold increase in 2−dCt of IFN score A in blood was 2.21 (95% CI
1.37, 3.53), while in non-lesional skin the fold increase was
markedly higher at 28.74 (95% CI 1.29, 639.48). The differential
increase in ISG expression in blood and skin was even more
extreme in SLE patients compared to healthy controls; in some
SLE patients, ISG expression in the skin was more than 5000
times higher than healthy controls. The mean fold increase was
7.80 (95% CI 4.75, 12.80) in blood compared to 479.33 (95% CI
39.32, 5842.78) in the skin. The increased epidermal expression of
ISGs was further confirmed by increased protein expression of the
interferon-induced GTP-binding protein MxA using immuno-
histochemistry (Supplementary Fig. 13). Non-lesional skin
biopsies from SLE patients (n= 3) showed the highest expression
of MxA followed by non-lesional skin from At-Risk individuals
(n= 3) in comparison with skin biopsies from healthy controls
(Fig. 7e).
Diffuse epidermal expression of type I IFNs in autoimmunity.
Given the extreme elevation of ISG expression in skin compared
to blood, we further analyzed skin biopsies from healthy controls
(n= 4), SLE patients (n= 6), and At-Risk individuals (n= 4).
Skin biopsies were obtained from active lesions of SLE patients,
whilst skin biopsies from At-Risk individuals had no clinical or
histopathological signs of inflammation. We performed in situ
hybridization using RNAscope technology to visualize the direct
expression of type I IFNs transcripts (IFNK, IFNA2) at a cellular
level in all skin biopsies obtained. Representative images of
positive and negative controls for in situ hybridization can be
seen in Supplementary Fig. 14.
As expected, skin biopsies from healthy controls with minimal
IFN score A in blood showed no expression of either IFNK or
IFNA2 (Fig. 7f). In contrast, the epidermis of At-Risk individuals
with high IFN score A in blood was also characterized by diffuse
expression of IFNK, although unlike SLE patients, there were no
clinical or histopathological features of inflammation (Fig. 7g).
Active skin lesions from SLE patients with high IFN score A in
blood also demonstrated diffuse expression of IFNK in the
epidermis (Fig. 7h). Regarding IFNA2 expression, we detected
expression in the dermis, possibly by fibroblasts as the IFNA2
signal was located within dense connective tissue. However,
notably, we did not see the expression of IFNK or IFNA2 in areas
of leucocyte infiltration (Supplementary Fig. 15).
To further evaluate the presence of pDCs in the skin biopsies,
staining for BDCA-4 (CD304) was performed using immuno-
fluorescence in non-lesional skin biopsies acquired from healthy
controls (n= 3), At-Risk individuals (n= 3), and patients with
SLE (n= 3). Although we validated the positivity of the pDCs for
the marker in cells isolated from PBMCs, we detected no BDCA-4
positive cells in any of the non-lesional skin biopsies we analyzed
(Supplementary Fig. 16).
Collectively, these results indicated that the high IFN activity
observed in both non-lesional and lesional skin, including at a
preclinical phase, was not mediated by infiltrating hematopoietic
immune cells. Instead, the in situ hybridization suggested that
non-hematopoietic cells, such as keratinocytes throughout
histologically normal skin, were responsible for type I IFN
production in scenarios where pDCs produced none.
Keratinocytes express type I IFN in preclinical autoimmunity.
To test the response of keratinocytes to a known environmental
trigger for cutaneous inflammation, we measured the expression
of type I IFN transcripts in the non-lesional skin of a patient with
clinically inactive SLE before and after UV provocation in vivo. In
a biopsy obtained before UV provocation, there was low IFNK
expression in the epidermis (Fig. 8a). We then obtained a second
biopsy after a standard diagnostic UV provocation using a solar
simulator at 1.5× minimal erythema dose on three consecutive
days. Following UV provocation, we observed a striking diffuse
increase in the expression of IFNK in the epidermis using in situ
Fig. 6 pDCs have features of cellular stress and immune senescence in autoimmunity. a Venn diagram showing the number of differentially expressed
transcripts (n= 80) common to both IFNlow and IFNhigh pDCs from SLE patients compared to pDCs from HC. b Reactome Pathway Enrichment in DEGs in
differentially expressed genes in IFNlow and IFNhigh pDCs from SLE patients shown in a. c Expression level of representative genes differentially expressed
in both IFNlow and IFNhigh pDCs from SLE patients in comparison with pDCs from HC. d Purified pDCs from freshly isolated PBMCs were hybridized
without (d; right) or with (d; left) telomere PNA probe. Gates were set in G0/1 phase for both sample cells (pDCs) and tetraploid control cells (1301 cell
lines). e Determination of the relative telomere length as the ratio between the telomere signal of pDCs purified from HC (n= 10) and SLE (n= 10) patients
and the control cells (1301 cell line) with correction for the DNA index of G0/1 cells. f Viable cells were defined as double negative when stained for annexin
V and 7-AAD; viability was assessed at 3 and 6 h after exposure to H2O2. One hundred percent of viable cells were defined by the number of cells alive of
the non-H2O2-exposed cells (0 μM) at the two time points. g Freshly isolated PBMCs from healthy donors (n= 4) were exposed to H2O2 (0–500 μM) for
15 min. After H2O2 exposure, cells were washed thoroughly and resuspended in a culture medium before they were stimulated with 2 μM ODN 2216 for 6
h. The production of IFN-α by pDCs was measured in viable cells by intracellular staining. Data are represented as mean ± SEM. ns not significant; *P <
0.05; ****P < 0.001. The unpaired two-tailed t-test (e), 1-way ANOVA (g).
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hybridization (Fig. 8b), similar to the expression observed in the
non-lesional skin of At-Risk individuals.
In order to confirm this cellular source of IFN, we studied the
IFN-producing capacity of keratinocytes in At-Risk individuals
and SLE patients in vitro. We isolated human keratinocytes and
dermal fibroblasts from non-lesional skin of healthy controls
(n= 3), At-Risk individuals (n= 5), and SLE patients (n= 5).
Keratinocytes isolated from lesional skin biopsies of patients with
cutaneous discoid lupus erythematosus (CDLE), who were ANA-
negative and had minimal IFN score A expression in blood, were
also used as a disease control (n= 3). Cells were cultured and
stimulated with TLR3 or RIG-I agonists, Poly(I:C) (1 μg/mL) or
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Poly(dA:dT) (100 ng/mL), respectively, for 6 and 24 h before the
expression of three subtypes of type I IFNs (IFNK, IFNA2, and
IFNB1) as well as type III IFN (IFNL1) was measured by qRT-
PCR.
At baseline, without exogenous stimulation, IFNK was
expressed by keratinocytes from At-Risk and SLE skin, but not
from healthy controls or CDLE. After either Poly(I:C) or Poly
(dA:dT) stimulation, this expression of IFNK by At-Risk and SLE
keratinocytes was further increased (Fig. 8c). For IFNB1, there
was no expression at baseline in any sample. However, after
stimulation with Poly(I:C) there was a trend to increased
expression for At-Risk keratinocytes and a significant increase
for keratinocytes from SLE and CDLE patients. IFNB1 expression
was also increased in keratinocytes of SLE patients after Poly(dA:
dT) stimulation but not in other conditions (Fig. 8d). In contrast,
IFNL1 expression was only observed in CDLE keratinocytes
following Poly(I:C) stimulation but not in the other conditions or
following Poly(dA:dT) stimulation (Fig. 8e). Finally, IFNA2
expression by keratinocytes was not found in any sample or
condition.
Matched dermal fibroblasts from the same skin biopsies of
these donors (in all four patient groups) showed no expression of
IFNK, IFNA2, IFNL1 at baseline or after stimulation Poly(I:C) or
Poly(dA:dT). Interestingly, only dermal fibroblasts from CDLE
patients showed a significant increase in IFNB1 expression after
Poly(dA:dT) stimulation, whilst only a trend was observed for
cells from At-Risk individuals and SLE patients (Supplementary
Fig. 17).
Discussion
The importance of type I IFNs in the pathogenesis of human
autoimmune connective tissue diseases such as SLE is now gen-
erally accepted based on genetic and gene expression data and
positive phase III clinical trials of IFN-blocking therapy46. But
IFNs form a complex system with multiple ligands and receptors
with overlapping functions, and all cell types potentially produ-
cing and responding to them. This complexity has left many
unanswered questions about their cellular source, mechanism of
dysregulation, and role in disease initiation and perpetuation. In
this study, by including large cohorts of At-Risk individuals with
functional, transcriptomic, and tissue data, we have been able to
answer some of these questions. Several lines of evidence clearly
indicated that, even in At-Risk individuals, pDCs have lost their
immunogenic functions, do not correlate with other immunologic
or clinical features of the disease, and are not active in tissue.
However, simultaneously we found that in histologically normal
skin keratinocytes produced type I IFNs with a marked con-
centration of IFN response at this site in the absence of infil-
trating leucocytes. Our results, therefore, locate the IFN response
in non-hematopoietic tissues prior to the onset of inflammation.
Plasmablasts, other B cell subsets, and follicular helper-like
T cells are expanded in patients with active SLE, upregulating
chemokine receptors, and correlating with disease activity47–50. In
contrast, we reported a marked reduction of circulating pDC
numbers even at a preclinical stage. Previous literature speculated
that this may indicate the migration of pDCs to inflamed
tissues51,52. This suggestion was based on the observation of
CD123 or CD303 positive cells on immunohistochemistry53.
Based on the hypothesis that pDC depletion would be effective for
SLE, a recent phase I clinical trial evaluated the depletion of
BDCA-2 (CD303) positive cells in SLE54. However, these markers
are not specific for pDCs, as we demonstrated that differentiated
monocytes express BDCA-2. Moreover, surface markers do not
indicate whether these CD123 or CD303 positive cells produce
type I IFNs.
If pDCs in SLE patients passed through an active phase, in
which they produced type I IFNs, followed by a senescent phase,
then we would expect to see both of these represented in our data
by populations of high and low producing pDCs, with variation
in these proportions according to the IFN score or disease
activity. We did not observe this in any of the ANA-positive
populations we studied, even in the At-Risk stage where there is
no organ inflammation, no immunosuppressive therapy, and
usually no progression to clinical autoimmunity. Instead, we
found universally impaired pDC function in SLE and pSS patients
and At-Risk individuals with loss of all immunogenic functions
and a transcriptomic profile related to senescence. These pDCs
did not exhibit any change in chemokine receptor expression,
indicating migratory properties, whilst we found no BDCA-4
positive cells in skin biopsies of these groups. The numbers and
function of blood pDCs bore no relationship with blood IFN
activity, disease activity, or therapy.
Telomere shortening, as we observed in At-Risk and SLE
pDCs, could indicate replicative senescence. However, this is
unlikely to explain our results. pDCs are a terminally differ-
entiated cell type. In normal circumstances, when they produce
type I IFNs, they do not proliferate. Other mechanisms may cause
shortening of telomeres and biological aging, such as mild oxi-
dative stress, leading to a similar phenotype55–57. Oxidative stress
is an important feature of lupus pathology, especially in T cells,
contributing to a range of disease-associated changes58. Notably,
age-induced cellular stress was shown to affect the IFN-α-
producing capacity of human pDCs by impairing IRF7 and PI3K
pathways59–61.
Other recent data had cast doubt on the contribution of pDCs
to the type I IFN activity seen in SLE. While attomolar con-
centrations of IFN-α protein was detected in pDCs of the
monogenic interferonopathy STING, this was not seen in SLE
samples62. However, responses to TLR agonists were not tested62.
In TREX1-deficient mice, there is a failure to regulate STING-
mediated antiviral response leading to aberrant type I IFN pro-
duction. This IFN response has been shown to initiate in non-
hematopoietic cells, similarly to our findings in humans63.
Moreover, experimental work on lupus-prone mice reported a
Fig. 7 Patients with SLE and At-Risk individuals have a diffuse expression of epidermal IFNK. Association of IFN score A with an active and inactive
mucocutaneous disease in SLE patients (a). Association of IFN score A with an active and inactive musculoskeletal disease in SLE patients (b). For
graphical representation, mean and SEM were transformed using 2−dCt so that higher expression was shown as a taller bar (a, b). Fold increase in IFN
score A of At-Risk individuals (c) in blood (2.21; 95% CI 1.37, 3.53) and skin (28.74; 95% CI 1.29, 639.48) compared to healthy controls. Fold increase in
IFN score A of SLE patients (d) in blood (7.80; 95% CI 4.75, 12.80) and skin (479.33; 95% CI 39.32, 5842.78) compared to healthy controls. e Percentage
of MxA expression at the protein level in skin biopsies of healthy controls (HC; n= 3), non-lesional skin biopsies of At-Risk individuals (At-Risk; n= 3), and
non-lesional skin biopsies of SLE patients (SLE; n= 3). Skin biopsies were hybridized using RNAscope in situ hybridization technology with custom-
designed target probes for IFNA2 and IFNK. Hybridization signals were amplified and detected using TSA Plus fluorescein (FITC) for IFNA2 and TSA Plus
Cyanine 3 (Cy3) for IFNK. Nuclei were highlighted using DAPI. Representative in situ hybridization images of f healthy control, g IFNhigh At-Risk individual
with no clinical or histopathological signs of inflammation, h IFNhigh SLE patient with an active skin lesion. Data are represented as mean ± SEM. Scale bars:
100 µm. ns= not significant; *P < 0.05; ***P < 0.01; ns= not significant. The unpaired two-tailed t-test (a, b), two-way ANOVA (e).
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gradual loss of pDC capacity to produce IFN-α at a late stage of
disease64,65. Importantly, murine models of chronic viral infec-
tion maintained a pool of functionally exhausted pDCs, a similar
state to what we describe in chronic autoimmunity in humans66.
Recent findings on systemic sclerosis reported the abnormal
expression of TLR8 in pDCs that leads to IFN-α production
suggesting a key pathological role of RNA-sensing TLR involve-
ment in the establishment of fibrosis67. However, in our RNA-
sequencing data in pDCs sorted from At-Risk individuals or SLE
patients, we could not confirm the positive expression of TLR8 in
any of the samples.
Within the pDC population, distinct subsets have been
described mediating different immune functions68. Single-cell
RNA-sequencing data revealed the diversification of human
pDCs in response to the influenza virus into three phenotypes
(P1-, P2-, P3-pDCs) with distinct transcriptional profiles and
functions69. In our study, pDCs from SLE patients were mostly
similar to the P1-phenotype, which represented the conventional
secretory function and morphology of pDCs. This is consistent
with our finding that SLE pDCs demonstrated decreased ability
to induce CD4+CD25highFoxP3+ T cells, the numbers and
function of which are known to be impaired in patients with
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active SLE70–72. Additionally, SLE pDCs differentially expressed
genes that are well-known to be involved in cellular senescence
and stress, negative regulation of TLR and MAPK pathways as
well as IL-10 signaling downstream, which can inhibit cytokine
production and survival of pDCs73–75. Similar to our findings in
pDCs, kidney infiltrating T cells in murine lupus have recently
been shown to exhibit an exhausted transcriptional signature and
phenotype76.
Cutaneous disease activity in SLE had previously been shown
to associate with a systemic ISG signature77. In our work, we
extend this finding by analyzing paired blood and skin samples to
demonstrate that the IFN score is markedly enriched in the skin,
even in the absence of clinical inflammation and in At-Risk
individuals. This is therefore suggestive of local production of IFN
in the skin prior to the onset of systemic disease.
IFN-κ is predominantly produced by human keratinocytes
with pleiotropic effects similar to IFN-α/β78. In SLE patients,
keratinocytes have been implicated in the pathogenesis of skin
injury by undergoing apoptosis or necrosis and eventually
releasing autoantigens79. Previous studies demonstrated that
keratinocytes from patients with cutaneous lupus erythematosus
presented increased production of IL-6 compared to healthy
controls, with type I IFNs enhancing this process80. In addition,
IFNK expression was reported to be significantly increased in
lesional skin of patients with cutaneous lupus erythematosus
related to photosensitivity81. By visualizing the direct expression
of type I IFN transcripts in human skin biopsies, we confirmed
and extended these findings. Diffuse expression of IFNK was seen
not only in the epidermis of lesional skin of SLE patients but,
more importantly, in the epidermis of non-lesional skin of ANA-
positive At-Risk individuals with high IFN activity in blood, who
had no clinical or histopathological features of inflammation. The
effect of UV light on inducing IFN-κ production by keratinocytes
has previously been demonstrated in vitro81. Here, we demon-
strated that UV provocation in vivo induced higher expression of
IFNK in the epidermis of SLE patients with inactive disease.
Notably, in vitro culture of keratinocytes showed high expression
of IFNK at baseline, whilst stimulation with TLR3 and RIG-I
agonists enhanced IFNK expression, even in At-Risk individuals.
Further, the types of IFN (kappa, beta, lambda) produced varied
between systemic and discoid lupus as well as different cellular
stimuli. These results, therefore, indicate the production of type I
IFNs by non-hematopoietic cells in the absence of production by
pDCs or tissue leucocytes early in the initiation of autoimmunity
and in a disease-specific manner.
In summary, while the importance of type I IFN in SLE is
undeniable, the reasons for the failure of normal regulation of its
production have never been clear. Our results indicate that tissues
such as the skin are not mere passive targets for leucocyte-
mediated immune processes but have an active role in generating
an IFN response, which dominates over inert pDCs. Immune
functions of non-hematopoietic tissues may have a role in
determining the clinical presentation of these heterogeneous
diseases. They may help to explain the resistance of tissue
inflammation to commonly used therapies that target leucocytes,
and instead point to therapeutic targets that lie outside the con-
ventional immune system. Further study of these tissues may
offer insights into the early events in the initiation of autoimmune
disease and therefore how these might be targeted for disease
prevention.
Methods
Patients and healthy volunteers. Peripheral blood and skin biopsies were
obtained from healthy individuals and patients from different disease groups (SLE,
pSS, At-Risk). Patients were recruited based on 2012 SLICC classification criteria
for SLE, 2016 ACR/EULAR classification criteria for pSS, while At-Risk individuals
were classified as ANA-positive, ≤1 SLE clinical criterion, symptom duration
<12 months, and treatment-naive. Supplementary Table 1 summarizes the char-
acteristics and treatment of SLE patients. Ethical approval was provided by Leeds
East–National Research Ethics Committee (REC 10/H1306/88) and all participants
gave written informed consent before participation.
Isolation of human peripheral blood cells. Human PBMCs were separated from
whole blood by a density gradient centrifugation method using Leucosep tubes
(Greiner Bio-One). pDCs were purified from freshly isolated PBMCs by negative
selection using the Diamond Plasmacytoid Dendritic Cell Isolation Kit II (Miltenyi
Biotec). Naive CD4+ T cells were purified by negative selection using the Naive
CD4+ T Cell Isolation Kit II (Miltenyi Biotec). Pre-enriched pDCs were sorted
using an antibody to BDCA-4 (Miltenyi Biotec). Cell sorting was carried out at the
SCIF Flow Cytometry and Imaging Facility of the Wellcome Trust Brenner
Building, University of Leeds, with a BD Influx 6 Way Cell Sorter (BD Biosciences).
Culture of human peripheral blood cells. Cells were cultured in RPMI medium
1640 with GlutaMAX supplement (ThermoFisher Scientific) containing 10% (vol/
vol) FBS and 100 U/mL penicillin/streptomycin. For cytokine production, PBMCs
were stimulated with 2 μM class A CpG (ODN 2216; Miltenyi Biotec) or 2 μM
ORN R-2336 (Miltenyi Biotec). For pDC/T-cell co-cultures, the cells were purified
as described above (isolation of human peripheral blood cells). Purified pDCs (1 ×
105) were cultured with autologous or allogeneic naive CD4+ T cells (5 × 105) for
5 days in the absence or presence of anti-CD3/CD28 beads (T-cell activation/
expansion kit; Miltenyi Biotec) at a bead-to-cell ratio of 1:2. Cytokine production
was measured by intracellular staining.
Flow cytometry. For cell surface staining, fluorochrome-conjugated monoclonal
antibodies against human CD3, CD4, CD19, CD14, CD56, CD11c, HLA-DR,
CD123, CD303, CD304, CD85g, CD85j, CD69, CD25 (Miltenyi Biotec), CD317
(BioLegend) and isotype controls were used. For intracellular staining, cells were
first stained for surface markers and then fixed and permeabilized using the
Intracellular Fixation & Permeabilization Buffer Set (eBioscience). Fluorochrome-
conjugated monoclonal antibodies against human IFN-α, TNF, IL-6, IFN-γ, IL-10
(Miltenyi Biotec), TLR9 (BD Biosciences), TLR7 (R&D Systems), and isotype
controls were used. For FoxP3 (Miltenyi Biotec) intracellular staining, cells were
first stained for surface markers and then fixed and permeabilized using the FoxP3
Staining Buffer Set (Miltenyi Biotec). Cell proliferation was measured using the
CellTrace Violet Cell Proliferation kit (ThermoFisher Scientific) according to the
manufacturer’s instructions. Flow cytometry was performed on LSRII (BD Bios-
ciences) or Cytoflex S (Beckman Coulter) and the data were analyzed using FACS
DiVA (BD Biosciences) or CytExpert (Beckman Coulter) software. A detailed table
of antibodies used for flow cytometry can be seen in Supplementary Table 8.
Quantification of gene expression in peripheral blood. Total RNA was extracted
from freshly isolated PBMCs using the Total RNA Purification Kit (Norgen Biotek)
according to the manufacturer’s instructions. RNA was reverse transcribed to
cDNA using the Fluidigm Reverse Transcription Master Mix buffer and gene
expression was measured by TaqMan assays (Applied Biosystems, Invitrogen). The
relative expression of specific transcripts (ISG15, IFI44, IFI27, CXCL10, RSAD2,
IFIT1, IFI44L, CCL8, XAF1, GBP1, IRF7, CEACAM1) was normalized with respect
to the internal standard (PP1A). IFN score A was calculated based on factor
analysis as the median dCT of these transcripts8.
RNA-sequencing data generation. RNA from sorted pDCs was extracted using
PicoPure RNA Isolation Kit (ThermoFisher Scientific) and quantified using the
Qubit RNA HS Assay Kit (ThermoFisher Scientific). RNA libraries were made by
using SMART-Seq V4 ultra low Input RNA Kit (Takara Bio USA) and Nextera XT
DNA Library Preparation Kit (Illumina) for NGS sequencing. Indexed sequencing
libraries were pooled and sequenced on a single lane on the HiSeq 3000 instrument
as 151 bp paired-end reads. Pooled sequence data was then demultiplexed using
Illumina bcl2fastq software allowing no mismatches in the read index sequences.
RNA-sequencing data processing and analysis. Raw paired-end sequence data
in Fastq format was initially analyzed using FastQC software in order to identify
potential issues with data quality. Cutadapt software was then used to remove
poor-quality bases (Phred quality score <20) and contaminating technical
sequences from raw sequenced reads. Contaminating technical sequences identified
at the initial QC stage were as follows:
CTGTCTCTTATA – Next Era Transposase Sequence
GTATCAACGCAGAGTACT– SmartSeq Oligonucleotide Sequence
dT30 – SmartSeq 3′ CDS Primer II sequence
Reads trimmed to fewer than 30 nucleotides and orphaned mate-pair reads
were discarded to minimize alignment errors downstream.
Reads were aligned to human hg38 analysis set reference sequences, obtained
from UCSC database82 using splicing-aware STAR aligner83 for RNA-Sequencing
data. STAR aligner was run in 2-pass mode, with known splice junctions supplied
in GTF file format, obtained from the hg38 RefSeq gene annotation table from the
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UCSC database using Table Browser tool84. The resulting alignments in the BAM
file format were checked for quality using QualiMap software85 and Picard tools86.
Picard tools were used to mark PCR/Optical duplicate alignments. Custom code
was used to filter out contaminating ribosomal RNA alignments, using ribosomal
RNA coordinates for hg38 analysis set reference obtained using the UCSC Table
Browser tool. The final alignment files were sorted and indexed using Samtools
software87 and visualized using IGV browser88.
Bioconductor R package RSubread89 was used to extract raw sequenced
fragment counts per transcript using the RefSeq hg38 transcript annotation set, as
before. Paired-end reads were counted as a single fragment and multi-mapping
read pairs were counted as a fraction of all equivalent alignments. Raw count data
were normalized for library size differences using median ratio method90, as
implemented in DESeq2 R Bioconductor package91. DESeq2 was also used to
perform additional data QC steps and differential expression analyses.
Differentially expressed gene expression was visualized as clustered heatmaps using
Pheatmap R package92 using log-transformed normalized gene expression values as
input. Gene functional and pathway enrichment analyses were performed using R
Bioconductor packages clusterProfiler93 and ReactomePA94. Additionally, KEGG95
pathways were visualized using Pathview package96.
Measurement of relative telomere length. Relative telomere length was mea-
sured using the Telomere PNA Kit/FITC for Flow Cytometry (Agilent) according
to the manufacturer’s protocol. Briefly, on a single-cell suspension consisting of
purified pDCs and control cells (1301 cell line; Sigma-Aldrich), the sample DNA
was denatured for 10 min at 82 °C either in the presence of hybridization solution
without probe or in hybridization solution containing fluorescein-conjugated PNA
telomere probe. Then hybridization took place in the dark at room temperature
overnight. The sample was then resuspended in an appropriate buffer for further
flow cytometric analysis. The data obtained were used for the determination of the
relative telomere length as the ratio between the telomere signal of each sample
(pDCs) and the control cell (1301 cell line) with correction for the DNA index of
G0/1 cells.
Oxidative stress assay. Freshly isolated PBMCs from healthy donors were
exposed to H2O2 (0–500 μM) for 15 min. After exposure, cells were washed
thoroughly and resuspended at 1 × 106 in a culture medium before they were
stimulated with 2 μM ODN 2216 (Miltenyi Biotech) for 6 h. The production of
IFN-α (Miltenyi Biotec) by pDCs was measured by intracellular staining as
described above. The viability of pDCs was assessed by staining the cells for
Annexin V (Miltenyi Biotec) and 7-AAD (Miltenyi Biotec) before data analysis
using flow cytometry.
Measurement of antigen uptake. pDCs were isolated from PBMCs (Miltenyi
Biotec) and were then cultured in RPMI medium 1640 with GlutaMAX supple-
ment (ThermoFisher Scientific) containing 10% (vol/vol) FBS and 100 U/mL
penicillin/streptomycin in a 96-well plate. Purified pDCs were cultured with or
without 10 μg/mL DQ Ovalbumin (Molecular Probes). After 18 h, the cells were
collected and then washed twice before data were analyzed using flow cytometry.
Samples from healthy controls (n= 3), At-Risk individuals (n= 3), and SLE
patients (n= 3) were used.
UV provocation. UV provocation was performed based on a published protocol
designed for use in clinical trials97,98. Briefly, a solar simulator was used in routine
clinical practice, which replicated the protocol of UV-A and UV-B provocation in a
single exposure. On day 1, four 1.5 cm2 areas of skin were exposed to solar
simulated radiation depending on skin type; 4, 8, 12, 16 J/cm2 for skin types I and
II, and 6, 12, 18, 24 J/cm2 for skin types III–VI. On day 2, the minimal erythema
dose was then determined. A 10 cm2 non-sun exposed area of skin was exposed to
minimal erythema dose × 1.5 on three consecutive days. A biopsy of the pre-
exposed and exposed area of skin was obtained when a reaction was seen clinically
(mean time to a positive reaction to provocation was 7 (±6) days, and rarely more
than 14 days).
Tissue section. Skin biopsies were obtained from healthy individuals and patients,
then snap-frozen in liquid nitrogen within 5 min, embedded in OCT, and stored in
a −80 °C freezer. Fresh frozen skin biopsies were cryosectioned to 10–20 μM,
placed on superfrost plus slides (ThermoFisher Scientific), and used for in situ
hybridization.
In situ hybridization and fluorescence microscopy. In situ hybridization of type
I IFNs transcripts in skin samples was performed using RNAscope Multiplex
Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics) according to manu-
facturer’s instructions. Briefly, cryosections were fixed and dehydrated before
exposure to hydrogen peroxide and protease treatment followed by hybridization
for 2 h with custom-designed target probes (IFNA2, IFNK). Appropriate positive
and negative controls were provided by the manufacturer. Hybridization signals
were amplified and detected using TSA Plus fluorescein and TSA Plus Cyanine 3
(Perkin Elmer) according to the manufacturer’s protocol. Nuclei were highlighted
using 4′,6-diamidino-2-phenylindole (DAPI). Slides were mounted using Prolong
Gold Antifade mounting medium (ThermoFischer Scientific) and dried overnight
in the dark at 4 oC. Images were acquired on a Nikon A1R confocal laser scanning
microscope system at ×20–×40 magnification. Images were analyzed in the Nikon
NIS Elements software.
In situ immunohistochemistry. Immunohistochemistry was utilized to detect
the protein expression of MxA protein. Human skin biopsies from healthy controls
(n= 3), At-Risk individuals (n= 3), and SLE patients (n= 3) were frozen unfixed
in optimal cutting temperature (OCT) compound (Tissue-Tek) for cryosectioning
and stored at 80 °C for future use. 5 µm-thick-frozen sections were cut using a Leica
CM3050S cryostat (Leica Microsystems Ltd) and mounted on Polysine (poly-L-
lysine coated) slides (ThermoFisher Scientific). Just before use, sections were
defrosted at room temperature for 3–5 min, fixed in ice-cold acetone for 7–10 min,
and subsequently rehydrated in 1x PBS for 5 min. Sections were then permeabilized
in a solution of 1× PBS containing 0.05% Tween-20 (Sigma-Aldrich) for 10 min.
Endogenous peroxidase activity was blocked by incubation in 3% H2O2 in (vol/vol)
methanol/de-ionized water for 30 min at room temperature followed by a brief
rinse in PBS. Nonspecific bindings were blocked using 2% Bovine Serum Albumin
(Sigma) in PBS for 30 min at room temperature, followed by incubation with
1:1000 human anti-MxA antibody (rabbit polyclonal, ab95926) in 1% normal
donkey serum (Sigma-Aldrich) in PBS overnight at 4 °C in a moist chamber to
avoid dehydration. After washing twice in PBS for 5 min, with an intermediate
wash in 0.05% solution of Tween-20 in PBS, sections were incubated with anti-
rabbit (SAB3700930) polyclonal biotin-conjugated secondary antibody (Sigma-
Aldrich) diluted 1:100 in 1% normal donkey serum in PBS for 30 min at RT.
Sections were washed as described above following by the application of Strepta-
vidin peroxidase (Sigma-Aldrich, S2438) at a dilution of 1:100 in PBS for 30 min at
RT. After a washing procedure, antibody binding was visualized by the addition of
the peroxidase substrate, 3-amino-9-ethylcarbazole (AEC Substrate Kit SK-4200,
Vector Laboratories). Chromogen formation was observed under a light micro-
scope, and the reaction was stopped by placing the slides in distilled water when
sufficient color was developed. Sections were dried and mounted with Aquamount
(VWR International). Potential nonspecific binding due to the secondary antibody
was checked by the replacement of the primary antibodies with 1% normal donkey
serum (negative control). The resulting staining was examined and photographed
using a Nikon Eclipse 80i light microscope with a Nikon ACT-2U photographic
system (Nikon).
In situ immunofluorescence. Slides containing frozen sections of skin biopsies
from healthy controls (n= 3), At-Risk individuals (n= 3), and SLE patients (n=
3) were defrosted at room temperature and fixed in ice-cold methanol for 10 min at
−20 oC and rehydrated in PBS for 5 min. Sections were then blocked in 10% fetal
calf serum (FBS) blocking solution in 1 % PBS for 90 min at room temperature.
This step was followed by incubation with rabbit monoclonal (ab81321) to BDCA-
4 (Abcam) at 1:20 dilution of 1% FBS overnight at 4 °C. After washing twice in PBS
for 5 min and an intermediate wash in PBS/Tween-20 (0.05%), sections were
incubated with a PE-conjugated donkey anti-rabbit secondary antibody (Jackson
ImmunoResearch Laboratories) at a dilution of 1:100 with 1% FBS, for 1 h at room
temperature. Slides were washed as above and were dried and mounted in Vec-
tashield Mounting Medium with 4,6-diamino-2-phenylindole (DAPI) (Vector
Laboratories). Finally, sections were viewed with a Leica DMIRB/E fluorescence
microscope (Leica Microsystems Ltd).
Culture of human keratinocytes and dermal fibroblasts. Human keratinocytes
and dermal fibroblasts were isolated from 3mm punch skin biopsies. The epi-
dermal component of the biopsy was placed in a T75 flask and cultured at 37 °C in
low glucose DMEM (Fischer Scientific) containing 10% (vol/vol) FBS (Fischer
Scientific) and 1% penicillin/streptomycin. The cells were passaged and sub-
cultured into a growth medium (PromoCell) for continuous culture. Keratinocytes
and dermal fibroblasts were passaged and plated in 24-well plates for subsequent
stimulation. At 90% confluence, cells were either untreated or treated with 1 μg/ml
Poly I:C (InvivoGen) or 100 ng/mL Poly dA:dT (InvivoGen) for 6 or 24 h.
Quantitative RT-PCR for keratinocytes and dermal fibroblasts. RNA was
extracted from keratinocytes and dermal fibroblasts using Quick-RNA MiniPrep
kit (Zymo Research) according to the manufacturer’s instructions. Extracted RNA
was reverse transcribed using the First Strand cDNA Synthesis kit (ThermoFisher
Scientific). The cDNA was then used in a qRT-PCR assay using QuantiFast SYBR
Green PCR kit (Qiagen). For the assay, the following QuantiTech primers were
used: IFNK (QT00197512; Qiagen), IFNB1 (QT00203763; Qiagen), IFNL1
(QT00222495; Qiagen), IFNA2 (QT00212527; Qiagen), U6snRNA (forward—5′-
CTCGCTTCGGCAGCACA-3′; reverse—5′-AACGCTTCACGAATTTGC-3′;
Sigma-Aldrich). For gene expression analysis, ddCt method was used and all
samples were normalized to the housekeeping gene (U6snRNA).
Statistical analysis. Statistical analyses were carried out with Prism software
(GraphPad). Continuous variables were compared using either Student’s t-test or
ANOVA followed by pairwise Tukey tests. Pearson’s correlation was used for
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associations. A P-value of ≤ 0.05 was considered significant (ns, not significant; *P
< 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). In all figures, error bars indicate
SEM unless it is stated otherwise.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA sequence data have been deposited in BioProject under accession code
PRJNA645252. All other data are available in the article and Supplementary files or from
the corresponding author upon reasonable request. Raw data are provided as a Source
Data file.
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